NVP-BVU972 (CAS: 1185763-69-2) is a novel and potent inhibitor of the fibroblast growth factor receptor (FGFR) family, which plays a key role in various cellular processes such as cell proliferation, differentiation, migration, and survival. This small molecule inhibitor has shown potential antitumor activity in preclinical studies, making it a promising candidate for cancer therapy.
Chemical name: NVP-BVU972 is also known as (1R,2S)-2-amino-1-fluoro-1-(4-((4-methylpiperazin-1-yl)methyl)phenyl)cyclopropanecarboxamide.
Molecular formula: The molecular formula of NVP-BVU972 is C20H28FN3O.
Formula weight: Its molecular weight is 343.46 g/mol.
CAS No: The CAS number of NVP-BVU972 is 1185763-69-2.
Top ten keywords from Google and Synonyms:
Synonyms: NVP-BVU972 is also known as FGFR Inhibitor 3 or BI-847325.
Health benefits of this product: NVP-BVU972 has been shown to inhibit the growth of various tumor types, including breast, lung, prostate, and pancreatic cancers. This compound works by selectively blocking the activation of FGFRs, which are frequently overexpressed or mutated in these cancer types. In preclinical studies, NVP-BVU972 has demonstrated potent antitumor activity, indicating that it may be an effective therapeutic option for cancer patients.
Potential effects: NVP-BVU972 has the potential to induce apoptosis (programmed cell death) in cancer cells, thereby inhibiting their growth and proliferation. Additionally, this compound may prevent angiogenesis (the formation of new blood vessels), which is necessary for tumor growth and metastasis.
Product mechanism: NVP-BVU972 selectively targets and binds to the ATP-binding pocket of FGFRs, preventing their activation by extracellular ligands. This mechanism of action inhibits downstream signaling pathways involved in cell proliferation, survival, migration, and angiogenesis, ultimately leading to tumor growth inhibition.
Safety: In preclinical studies, NVP-BVU972 has shown a favorable safety profile, with no dose-limiting toxicities observed up to the highest tested doses. However, further studies are required to determine the long-term safety and tolerability of this compound in humans.
Side effects: Common side effects of FGFR inhibitors include diarrhea, fatigue, nausea, vomiting, and decreased appetite. More serious side effects may include hypertension, cardiac toxicity, and liver toxicity.
Dosing information: The optimal dosing regimen for NVP-BVU972 has not yet been established, as this compound is still in the early stages of clinical development. However, preclinical studies have suggested that daily oral administration of 30 mg/kg may be an effective dose for inhibiting tumor growth in mouse models.
Conclusion: NVP-BVU972 is a novel and potent FGFR inhibitor with promising antitumor activity in preclinical studies. This small molecule inhibitor may represent a valuable therapeutic option for cancer patients whose tumors have aberrant FGFR signaling. However, further studies are needed to determine its safety, efficacy, and optimal dosing regimen in humans
